European Commission Approves Pfizer's VELSIPITY[R] for Patients with Moderately to Severely Active Ulcerative Colitis

MLA

“European Commission Approves Pfizer’s VELSIPITY[R] for Patients with Moderately to Severely Active Ulcerative Colitis.” Business Wire, 19 Feb. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.782999309&authtype=sso&custid=ns315887.

APA

European Commission Approves Pfizer’s VELSIPITY[R] for Patients with Moderately to Severely Active Ulcerative Colitis. (2024, February 19). Business Wire.

Chicago

Business Wire. 2024. “European Commission Approves Pfizer’s VELSIPITY[R] for Patients with Moderately to Severely Active Ulcerative Colitis,” February 19. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.782999309&authtype=sso&custid=ns315887.